Remove 2012 Remove Kidney Disease Remove Preserved Ejection Fraction
article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

article thumbnail

Characterisation of the octogenarians presenting to the diagnostic heart failure clinic: SHEAF registry

Open Heart

Results Data were collected in April 2012 to January 2014 and in June 2021 to December 2022. HF with preserved ejection fraction (HFpEF) was the most common phenotype and increased significantly compared with the first period (46.3% Statistical significance is determined at p<0.05. and 29.2%, p<0.001).